Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Richter

Gastroenterology West Columbia, SC Medical Doctor

NPI 1821202821 CMS profile 83338

131 Summerplace Dr, West Columbia, SC 29169

Open in the dashboard

General payments

$6,557

437 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Richter of West Columbia, SC is reported in the CMS Open Payments database as having received $6,557 across 437 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $833 54
2024 General $1,148 75
2023 General $1,324 91
2022 General $1,596 90
2021 General $619 55
2020 General $128 9
2019 General $909 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Richter
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to James Richter were reported at $833. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year James Richter Gastroenterology median Middle half National median
2019 $909 $417 $126–$1,100 $163
2020 $128 $224 $74–$624 $114
2021 $619 $352 $106–$1,054 $132
2022 $1,596 $448 $129–$1,270 $149
2023 $1,324 $533 $150–$1,390 $160
2024 $1,148 $605 $160–$1,606 $164
2025 $833 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,010 171 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $636 40 payments
  3. Pfizer Inc. $513 29 payments
  4. Celgene Corporation $430 28 payments
  5. QOL Medical, LLC $283 14 payments
  6. Janssen Biotech, Inc. $272 16 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $234 13 payments
  8. Ironwood Pharmaceuticals, Inc $228 14 payments
  9. Genzyme Corporation $201 9 payments
  10. Merck Sharp & Dohme Corporation $197 11 payments
  11. Other $1,553 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,515 433 payments
  2. Education $30 3 payments
  3. Consulting Fee $11 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $658 33 payments
  2. LINZESS Gastroenterology $579 84 payments
  3. CREON $550 77 payments
  4. XIFAXAN $529 31 payments
  5. XELJANZ $496 28 payments
  6. ZEPOSIA $412 27 payments
  7. SKYRIZI $394 16 payments
  8. MAVYRET $292 20 payments
  9. STELARA $258 15 payments
  10. Linzess Gi $228 14 payments
  11. Other $3,464 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,860

Median for Gastroenterology: 569

Drug cost

$448,969

Median for Gastroenterology: $104,976

Branded share of claims

35.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $102,521
Creon Lipase/Protease/Amylase Brand 29 $86,591
Xifaxan Rifaximin Brand 20 $59,204
Linzess Linaclotide Brand 61 $52,297
Trulance Plecanatide Brand 23 $21,236
Motegrity Prucalopride Succinate Brand 23 $19,449
Viberzi Eluxadoline Brand 13 $18,163
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 80 $13,670
Mesalamine Generic 22 $12,970
Dexlansoprazole Dr Dexlansoprazole Brand 18 $7,203

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$291,030

Medicare's payments for the services billed

Medicare patients

1,571

Average age 74

Services billed

4,040

913 women, 658 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 35%
Diabetes 31%
Chronic kidney disease 29%
Depression 23%
Heart failure 21%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $129
$129 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $66
  • AbbVie, Inc. $56
$122 61 —
SKYRIZI
  • AbbVie, Inc. $110
$110 — —
OMVOH
  • Lilly USA, LLC $103
$103 — —
DUPIXENT
  • GENZYME CORPORATION $64
  • Regeneron Healthcare Solutions, Inc. $25
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record